UPDATE -- X-ray contrast case: Bracco wins $11.4 M in damages from GE

March 30, 2009 DiagnosticImaging.com. UPDATE -- X-ray contrast case: Bracco wins $11.4 M in damages from GE By Greg Freiherr Buoyed by last week's U.S. District Court decision, Bracco Diagnostics is anything but shy about saying GE Healthcare used "false and misleading advertising and marketing" to gain an advantage for its Visipaque x-ray contrast agent over Bracco's Isovue product. But how -- or even whether -- the company will use the legal finding in its future marketing of Isovue is a matter of speculation the company is not willing to address, at least not publicly. "We cannot comment on our ongoing marketing plans," said a Bracco spokeswoman, "but we are pleased with the outcome of the litigation and think healthcare providers have a right to receive accurate scientific information. They have a right to know that the court ruled that GE Healthcare had engaged in false and misleading advertising and marketing."

See full article and related articles at DiagnosticImaging.com
This article was republished with permission from CMPMedica, LLC